Taysha Gene Therapies
Taysha halts gene therapy for rare nerve disease after FDA and Astellas feedback
Anika Sharma
Astellas has declined the opportunity to exercise an option for an asset from Taysha Gene Therapies. Taysha, facing study design ...
